Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    19109574 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Unknown  WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides
Condition: Systemic Wegener's Granulomatosis
Interventions: Drug: Azathioprine: 2 mg/kg/day;   Drug: methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week

Indicates status has not been verified in more than two years